Donate-Correa Javier, Luis-Rodríguez Desirée, Martín-Núñez Ernesto, Tagua Víctor G, Hernández-Carballo Carolina, Ferri Carla, Rodríguez-Rodríguez Ana Elena, Mora-Fernández Carmen, Navarro-González Juan F
Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain.
GEENDIAB (Grupo Español para el estudio de la Nefropatía Diabética), Sociedad Española de Nefrología, 39008 Santander, Spain.
J Clin Med. 2020 Feb 7;9(2):458. doi: 10.3390/jcm9020458.
One of the most frequent complications in patients with diabetes mellitus is diabetic nephropathy (DN). At present, it constitutes the first cause of end stage renal disease, and the main cause of cardiovascular morbidity and mortality in these patients. Therefore, it is clear that new strategies are required to delay the development and the progression of this pathology. This new approach should look beyond the control of traditional risk factors such as hyperglycemia and hypertension. Currently, inflammation has been recognized as one of the underlying processes involved in the development and progression of kidney disease in the diabetic population. Understanding the cascade of signals and mechanisms that trigger this maladaptive immune response, which eventually leads to the development of DN, is crucial. This knowledge will allow the identification of new targets and facilitate the design of innovative therapeutic strategies. In this review, we focus on the pathogenesis of proinflammatory molecules and mechanisms related to the development and progression of DN, and discuss the potential utility of new strategies based on agents that target inflammation.
糖尿病患者最常见的并发症之一是糖尿病肾病(DN)。目前,它是终末期肾病的首要病因,也是这些患者心血管发病和死亡的主要原因。因此,显然需要新的策略来延缓这种疾病的发生和发展。这种新方法应超越对高血糖和高血压等传统危险因素的控制。目前,炎症已被认为是糖尿病患者肾脏疾病发生和发展的潜在过程之一。了解引发这种最终导致DN发生的适应性免疫反应的信号和机制级联至关重要。这些知识将有助于识别新的靶点并促进创新治疗策略的设计。在这篇综述中,我们重点关注与DN发生和发展相关的促炎分子的发病机制和机制,并讨论基于针对炎症的药物的新策略的潜在效用。